Molecular Partners AG ADR - Asset Resilience Ratio
Molecular Partners AG ADR (MOLN) has an Asset Resilience Ratio of 19.76% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read MOLN current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Molecular Partners AG ADR's Asset Resilience Ratio has changed over time. See Molecular Partners AG ADR (MOLN) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Molecular Partners AG ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Molecular Partners AG ADR market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $22.16 Million | 19.76% |
| Total Liquid Assets | $22.16 Million | 19.76% |
Asset Resilience Insights
- Good Liquidity Position: Molecular Partners AG ADR maintains a healthy 19.76% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Molecular Partners AG ADR Industry Peers by Asset Resilience Ratio
Compare Molecular Partners AG ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Molecular Partners AG ADR (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Molecular Partners AG ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 53.97% | $85.56 Million | $158.53 Million | -6.31pp |
| 2023-12-31 | 60.29% | $119.58 Million | $198.35 Million | -1.18pp |
| 2022-12-31 | 61.47% | $161.20 Million | $262.26 Million | +26.14pp |
| 2021-12-31 | 35.33% | $61.00 Million | $172.67 Million | +14.00pp |
| 2020-12-31 | 21.33% | $40.00 Million | $187.55 Million | +2.87pp |
| 2019-12-31 | 18.46% | $19.37 Million | $104.94 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $155.16 Million | -- |
| 2017-12-31 | 6.75% | $9.74 Million | $144.42 Million | -9.81pp |
| 2016-12-31 | 16.56% | $30.49 Million | $184.10 Million | +7.44pp |
| 2015-12-31 | 9.13% | $20.02 Million | $219.40 Million | -- |
About Molecular Partners AG ADR
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more